Quantum Biopharma Class B Subordinate Voting Shares
QNTM
17 hedge funds and large institutions have $895K invested in Quantum Biopharma Class B Subordinate Voting Shares in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
2.05% less ownership
Funds ownership: 3.83% → 1.78% (-2%)
62% less capital invested
Capital invested by funds: $2.38M → $895K (-$1.48M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MG
Marex Group
London,
|
+$265K |
| 2 |
Morgan Stanley
New York
|
+$48K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$11.8K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$9.89K |
| 5 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$4.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$733K |
| 2 |
VF
Virtu Financial
New York
|
-$338K |
| 3 |
LPL Financial
San Diego,
California
|
-$221K |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$14.2K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$11K |
QNTM Hedge Fund Activity: Q3 2025 in Review
17 of the 7,625 institutional investors tracked by Wall St. Rank reported a position in Quantum Biopharma Class B Subordinate Voting Shares (QNTM) for Q3 2025, worth a combined $895K — down 62% from $2.38M a quarter earlier.
Fund positioning in QNTM was balanced in Q3 2025: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 3 trimmed.
The largest buyer was Marex Group, opening a new position worth an estimated $265K. The largest seller was UBS Group, cutting an estimated $733K.
- 17 institutional investors held Quantum Biopharma Class B Subordinate Voting Shares (QNTM) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $895K of Quantum Biopharma Class B Subordinate Voting Shares stock for Q3 2025, down 62% quarter-over-quarter.
- 4 funds opened new Quantum Biopharma Class B Subordinate Voting Shares positions in Q3 2025 and 4 closed out, a net change of 0 holders.
- The largest Quantum Biopharma Class B Subordinate Voting Shares buyer in Q3 2025 was Marex Group, an estimated $265K added.
- The largest Quantum Biopharma Class B Subordinate Voting Shares seller in Q3 2025 was UBS Group, an estimated $733K sold.
Based on aggregated 13F filings for Q3 2025.